Please assess the completion status of the following clinical trial:

Trial Title: Prospective Cohort Study to Evaluate Safety/Immunogenicity of Butantan Influenza Vaccine in Healthy Adults/Elderly

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults, male or female aged 18 to 59~* Elderly aged 60 years completed and above~* To be available to participate in the study throughout its duration (approximately 21 days)~* To have medical indication to be vaccinated against influenza~* To demonstrate intention to participate in the study, as documented by signature in the study´s informed consent form.~Exclusion Criteria:~* Evidence of active neurological, cardiac, pulmonary, hepatic or renal disease as clinical history and/or physical examination (except hypertension under control among the elderly)~* Compromised immune system diseases including: HIV, diabetes mellitus, cancer (except basal cell carcinoma) and autoimmune diseases~* Behavioral, cognitive or psychiatric disease that in the opinion of the principal investigator or his representative physician, affects the participant ability to understand and cooperate with all study protocol requirements~* Abusive usage of alcohol or drugs in the past 12 months that has caused medical, professional or family problems, indicated by clinical history~* Known systemic hypersensitivity to eggs or to any component of the vaccine~* History of severe adverse reaction after previous administration of an Influenza vaccine within 6 weeks following vaccination~* History of Guillain-Barre Syndrome or other demyelinating disease~* Diagnosis of asthma with a history of hospitalization in the last six months due to illness~* Suspected or confirmed fever in the 3 days prior to vaccination or axillary temperature greater than 37.8 ° C on the day of vaccination~* Use of corticosteroids (except topical or nasal) or other immunosuppressive drugs within 42 days before study initiation/baseline. It will be considered immunosuppressive dose of corticosteroids the equivalent to a dose ≥10 mg of prednisone per day for over 14 days~* Impaired coagulation due to chronic disease or due to use anticoagulant medication (warfarin or heparin) in the 7 days preceding vaccination~* Have received live virus vaccine within 28 days or killed virus vaccine in the last 14 days prior to vaccination, or have a scheduled immunization during the first 21 days after vaccination~* Have received influenza vaccine in the past 6 months;~* History of asplenia~* Have received blood products in the past 6 months, including transfusions or immunoglobulin, or scheduled administration of blood products or immunoglobulin for the first 21 days after vaccination~* have a counterindication for Influenza vaccination, including allergy to egg proteins~* Use of any investigational product within 42 days before vaccination;~* Any other condition that might put in risk the safety/rights of a potential participant or hurdle his/her compliance with this protocol in investigator's opinion or his representative physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy adults group (Type: None): Healthy adults aged 18 to 59 years Butantan Fragmented Inactivated Trivalent Influenza Vaccine
- Elderly group (Type: None): Elderly aged over than 60 years completed Butantan Fragmented Inactivated Trivalent Influenza Vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).